Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)

Prostate Cancer Clinical Trial

— PHS-02  

Official title:

Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01191931
• Other study ID #: CR2P00113
• Status: Completed
• Phase: N/A
• First received: August 30, 2010
• Last updated: October 26, 2012
• Start date: February 2008
• Est. completion date: June 2012

Study information

• Verified date: October 2012
• Source: Advanced Medical Diagnostics s.a.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Ethics CommitteeGermany: Ethics CommissionCzech Republic: Ethics CommitteeHungary: Institutional Ethics CommitteeUnited Kingdom: National Health Service
• Study type: Observational

Clinical Trial Summary

Study design:

-The study will be a phase I like study to assess the extent to which prostate HistoScanning (PHS, the index test) can identify and characterize foci of prostate cancer when compared to histological samples harvested during radical prostatectomy (the reference test). The study will comprise 3 steps: first, defining the most suitable method for matching the TRUS (TransRectalUltrasonography) to histology (step 1); second, refining the algorithms (training set); third, verification of the PHS performances (test set).

Study objectives:

• Primary Objective:

• To evaluate the extent to which PHS can discriminate between malignant lesions of the prostate versus non-malignant tissue in 3D RF TRUS data using radical prostatectomy histological step sectioning as the reference test.

• Secondary Objectives:

• To adapt and refine PHS tissue characterisation algorithms using RF data that were previously developed using grey-level data as input.

• To assess the accuracy of PHS in predicting the volume of prostate cancers determined by histology.

• To assess the ability of PHS to rule in or rule out the presence of cancer > or = 0.5 cc and of > or = 0.2 cc as determined by histology.

• To evaluate the ability to discriminate primary Gleason pattern 4 and 5 versus 3 or less in tumours > or = 0.5 cc and > or = 0.2 cc.

• To assess the ability of PHS to correctly risk stratify patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age: >or=18 year-old

• Histologically (positive biopsy) proven prostate cancer with primary and secondary Gleason patterns attributed.

• Patient planned to undergo radical prostatectomy

• Prostate cancer is deemed to be organ confined (T1-T2, Nx or No, Mx or Mo)

• No prior treatment for prostate cancer, including any type of hormonal therapy

• No major calcification is noted during the TRUS (i.e. (Diameter >or=5 mm, spread all over the prostate or blocking to much of the ultrasound signal).

• Patient willing to give written informed consent

Exclusion Criteria:

• Patients who are either unsuitable or unwilling to enter the study or to proceed to surgical investigation.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Locations

Country	Name	City	State
Belgium	Bordet Institute	Brussels
Belgium	UZ-Brussel	Brussels
Czech Republic	Olomouc Hospital	Olomouc
Germany	Universitätsklinikum Tübingen	Tübingen
Hungary	Semmelweis University	Budapest
United Kingdom	Imperial College Healthcare NHS Trust, Charing Cross Hospital	Hammersmith	London
United Kingdom	University College London Hospital (UCLH)	London

Sponsors (1)

Lead Sponsor	Collaborator
Advanced Medical Diagnostics s.a.

Countries where clinical trial is conducted

Belgium,  Czech Republic,  Germany,  Hungary,  United Kingdom, 

References & Publications (6)

Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, Nir D, Michielsen D, Bleiberg H, Egevad L, Emberton M. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008 Feb;101(3):293-8. Epub 2007 Oct 8. — View Citation

Braeckman J, Autier P, Soviany C, Nir R, Nir D, Michielsen D, Treurnicht K, Jarmulowicz M, Bleiberg H, Govindaraju S, Emberton M. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int. 2008 Dec;102(11):1560-5. doi: 10.1111/j.1464-410X.2008.07878.x. Epub 2008 Aug 14. — View Citation

Lucidarme O, Akakpo JP, Granberg S, Sideri M, Levavi H, Schneider A, Autier P, Nir D, Bleiberg H; Ovarian HistoScanning Clinical Study Group. A new computer-aided diagnostic tool for non-invasive characterisation of malignant ovarian masses: results of a multicentre validation study. Eur Radiol. 2010 Aug;20(8):1822-30. doi: 10.1007/s00330-010-1750-6. Epub 2010 Mar 20. — View Citation

Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L, Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M, Steuber T. Accuracy of HistoScanning™ for the prediction of a negative surgical margin in patients undergoing radical prostatectomy. BJU Int. 2013 Jan;111(1):60-6. doi: 10.1111/j.1464-410X.2012.11396.x. Epub 2012 Aug 9. — View Citation

Simmons LA, Autier P, Zát'ura F, Braeckman J, Peltier A, Romic I, Stenzl A, Treurnicht K, Walker T, Nir D, Moore CM, Emberton M. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™). BJU Int. 2012 Jul;110(1):28-35. — View Citation

Vaes E, Manchanda R, Nir R, Nir D, Bleiberg H, Autier P, Menon U, Robert A. Mathematical models to discriminate between benign and malignant adnexal masses: potential diagnostic improvement using ovarian HistoScanning. Int J Gynecol Cancer. 2011 Jan;21(1):35-43. doi: 10.1097/IGC.0b013e3182000528. — View Citation